INTRODUCTION

W ith its roots in the 19
th century, what is known today as the modern biopharmaceutical industry has only within the last 40 years encountered a significant disruption to its historically prevalent business model. The revolution in biotechnologies responsible for this disruption has affected not only biopharmaceutical companies themselves but 
AbstrAct
Research on business model innovation for the biopharmaceutical industry continues to be an area of high global interest due to the combination of industry innovation challenges and global macroeconomic pressures. Through the use of a systematic literature review, this research explores academic literature published from 1976 to 2013 that has addressed business model relevant factors and dynamics in the biopharmaceutical industry. 305 relevant publications were identified, analyzed, and inductively categorized based on the similarity of their conversations into twelve categories. The authors find that opportunities for business model innovation in the biopharmaceutical industry lie in five key areas: External Orientation, Learning Capabilities, Cluster Participation, Qualified Business Management Team and Organization Controls. This research provides not only insight into opportunities for business model innovation specific to this industry but also can be used independently as a valuable reference tool for similar research.
importantly, also the entire ecosystem of supporting stakeholders.
From the late 1970's, there has been a literal explosion of new biotechnology development and commercialization by thousands of researchers and companies across the world. Though the potential that biotechnology showed as a potential source for new therapies was exciting in its own right, it was the 1976 founding of Genentech as the world's first dedicated biotechnology company 1 and its collaborative 1982, development and market launch of its rDNA based synthetic human insulin with Eli Lilly & Co.
2 that showed would-be new biotech entrants and venture investors that intellectual property (IP) could be packaged and sold independently of having a final product. This key event thus ignited an explosion of thousands of new biotechnology firms which have in turn driven hundreds of new biotechnology derived therapies to market approval. 4 Prior to 1976, one would need to go back 32 years, all the way to the 1944 founding of Syntex, to find the previous instance where a new successful research-based pharmaceutical company was founded. 3 The challenge this presented to the industry was that because this biotechnology knowledge base is both complex and expanding and its sources of expertise are widely dispersed, the locus of innovation is found in networks of learning, rather than in individual firms. 5 Therefore, being adept at operating in a world of external collaboration is critical. However,the full vertically integrated business model (FIPCO) that had dominated the biochemistry based pharmaceutical industry for over 100 years, tends to be internally focused and thus limited in its ability to maintain by itself a needed level of expertise in this new, increasingly diverse and globally dispersed family of technologies.
Therefore, with Eli Lilly generally leading the way, despite the limitations of their vertically integarted structures, pharmaceutical firms soon started seeking opportunities and innovation externally by collaborating with these new diverse sources of technological expertise. In doing so, the industry started to fragment from the traditional silos of internal expertise and in doing the distinction between what is a pharmaceutical firm and what is a biotechnology firm took its first steps down a path to becoming less obvious. Indeed, it is now quite common for pharmaceutical companies to use biotechnologies to either support their own pharmaceutical R&D efforts 6 or even market and distribute a pure biotechnology directly, like Pfizer Inc.'s 2002 agreement with Serono SA to market and co-promote Rebif (interferon beta-1a), a treatment for multiple sclerosis. 7,i Unfortunately, despite biotechnology's early promise for more efficient research, productivity and cost remain significant concerns for this $1.2 trillion global industry. 8, 9 Indeed, the rate of output productivity for research and development (R&D) is actually decreasing relative to the increase of the productivity of its technological inputs. Like the historical development i Indeed, because of this muddling of technological focus and the consequent plausibility that both industries will eventually become indistinguishably integrated, for this research they are primarily treated as the same industry. As such, the terms biopharmaceutical industry or biopharmaceutical will be used to encompass both the traditional pharmaceutical industry and the medical biotechnology industry. Where it is relevant for clarity to separate them, this will be done.
of computer microprocessors, biotechnologies associated with R&D inputs have also been following Moore's Law, a term for the exponential improvements over time in technological fields. 10 For example, since the early 1980's DNA sequencing has become over two billion times less expensive to perform, it takes 100,000 less man hours to calculate 3D protein structures via x-ray crystallography than it did 50 years ago and high throughput screening has reduced the cost of testing drug-like molecules against protein targets by around 10 times per decade. 11 However, in contrast to these technological inputs, the therapeutic outputs of this industry follow what Scannell et al. 11 paradoxically coin as Eroom's Law (Moore's Law spelled backward). They point out how the inflation-adjusted R&D spend per molecule brought to market over the last 60 years has risen by over 100 times. Despite the billions of dollars that the industry collectively spends on R&D annually, the rate of output of new therapies is declining versus historical productivity levels. Indeed, the year 2010 saw the lowest number of New Molecular Entities (NME) ii applications by major pharmaceutical companies in the previous ten years. Moreover, the number of drugs entering Phase I and Phase II clinical trials fell 47% and 53% in 2010 over 2009. For Phase III trials the number is 55%. 12 Clearly, this lower R&D productivity stresses any company's financial health, especially those whose existing product sales are under threat from patent expiration and the resulting generic competition.
In part due to these issues, with an average R&D spend of 14%-15% of total revenue, it remains one of the most research intensive and costly industries in the world. 13 To the point of marketing approval, a typical candidate therapy costs between USD $559 and USD $672 million (2005 dollars) out-of-pocket over an average period of 8 years.
iii, 14 Unfortunately, the ability for companies to cover these costs will become more challenging due to changing global demographics and market conditions which will force global governments and private third party insurance payers to place increasing pressures on this industry's margins. Key among these will be the large ii NME -New Molecular Entity applications, a common industry indicator of R&D innovation. iii Importantly, these calculations do not include full R&D costs. To do so, one would also need to account for the cost of capital over this lengthy period of time, the expected return that the company or its investors forego vs. an equally risky investment. Applying these considerations, the average cost per candidate therapy increases to $1.3 billion.
14 bubble of the population that is currently entering the elderly demographic in key western markets. In the USA, for example, the first members of this "Baby Boom" generation started turning 65 in 2011. By 2029, when all of the baby boomers will be 65 years and over, more than 20 percent of the total U.S. population will be over the age of 65. 15 Since today this population makes up only 14.5% of the population 16 and due to the fact that this segment are overwhelmingly the predominant consumers of health care resources, currently at 34%
17 not difficult to see that this resulting progressive increase in healthcare utilization will force global government and third-party health care payers to continue to increase their pressure on the biopharmaceutical industry for products with greater marginal innovativeness and at lower prices.
As a result, there certainly exists a need for business models that provide more efficient and less costly ways of researching, developing and bringing life changing medical therapies to market in a commercially successful and sustainable way. Unfortunately, explicit research in this area is lacking. Though business models have implicitly been an important part of economic behavior and understanding for hundreds of years, it has been only recently that they have been an explicit focus of academic research. Indeed, Teece 18 and Osterwalder & Pigneur 19 cite the first appearance of the term "business model" in an academic journal to be 1957 20 and in the title of a paper to be 1960. 21 However it was not until the mid 1990s with the advent of the Internet and information technologies (IT) that the explicit concept of the business model became prevalent in academic and industry journals, where it has since exploded as a focus for researchers. 22 This story is similar for the biopharmaceutical industry.
Thus, there is an acute need to identify and assess key business model dynamics that can be helpful. Toward addressing this need, the focus of this research is to explore the universe of literature published since 1976 that has addressed business model relevant factors and dynamics in the biopharmaceutical industry and inductively mine this literature for insights into the opportunities for business model innovation. More specifically, using the method of a systematic literature review, the objectives of this research paper are:
• to deliver a state of the art report on business model relevant research conducted specifically for the biopharmaceutical industry.
• to suggest a categorization and linkedbased mapping of the identified literature by analyzing their respective "conversations" (core findings).
• to identify the evolution of this research, current research gaps and directions for potential future research.
The remainder of this article is structured as follows. A section on research method will provide a rationale for the use of a systematic literature review in this research and subsequently describe the detailed protocol followed. This will be followed by results and categorization which will provide the key results of the review including a detailed categorization and narrative of the captured literature. The findings are then discussed in light of the categorizations. Finally, the implications of our findings for researchers and practitioners are highlighted alongside opportunities for further research in the conclusion.
ReseaRCh MeThOD
Prior to starting this research, a review protocol for a systematic literature review was developed. This protocol established the research parameters including explicit descriptions and the order of the steps to be followed. The first step explicitly established the key question for the focus of this research: "How, through the use of business model innovation, can the biopharmaceutical industry continue to drive product innovation while at the same time reduce the time and costs that it takes to get a drug to market?" Following this, a specific year range was defined in order to limit the universe of publications to those years most meaningful to answering the key question. In this regard, 1976 was used as the start of the year range since it is the founding year of Genentech, the first fully dedicated biotechnology company.
1 Prior to this date, business models in this industry were relatively stable in that they overwhelmingly followed a fully integrated model (FIPCO). 23 The year 2013 was used as the end of the year range as this was the current year at the time of the start of this research.
After establishing the year range, the third step defined the publication universe that would be included. These publications were limited to those international peer-reviewed academic publications, and leading practitioner oriented journals that are included in the Thomson Reuters maintained Web of Science database. Since the Web of Science is both comprehensive and employs a strict inclusion evaluation processes, it was used as a general proxy for research quality. 24 Once these framing parameters were defined, a specific two level search strategy, first and second level search, was developed to ensure a systematic and comprehensive capture of all relevant publications. and the definition of a business model in many ways depends on the perspective of an author or how they are using the term. 25 Therefore, a decision was made to encompass all factors along the complete spectrum of the biopharmaceutical value chain that would encompass or be largely associated with the commercial translation of research. Based on this, a list of search terms was developed which were felt to cumulatively provide a sufficiently comprehensive level of inclusion criteria to capture the relevant universe of publications needed. Moreover, a similar definition challenge existed with the terms "pharmaceutical industry", "biotechnology industry" and "biopharmaceutical industry" and what they respectively encompass. Here it was determined to narrow the use of terminology to just biotechnology. Due to the significantly increasing co-dependence of research and commercial activities between the two areas, a sharp and clear distinction between them is now less meaningful for the purposes of business model innovation. As such, it was determined that a focus on the term biotechnology will capture enough of pharmaceutical business model dynamics to be sufficient for the purposes of this paper.
As shown in Table 1 below, all terms were then formatted into 18 separate "search strings" and entered into the EBSCO Business Source Complete publication database search engine and results captured. The EBSCO database was chosen due to it being among the largest and most comprehensive databases for business oriented scholarly full-text journals versus other popular databases.
27,28
For these search results, clear pre-established criteria for study inclusion and exclusion were applied so as to exclude marginally relevant articles. Inclusion criteria were customized from Zott, et al. 29 and include:
• An article must deal with the concept of business model or its relevant building block dynamics in a non-trivial and nonmarginal way.
• An article must deal with the concept of business model as a construct centered on business firms or on a dynamic directly related to the business firm's ability to commercialize its technology or service.
Exclusion criteria were also adopted and included published books iv , government and NGO reports, editorials and book reviews, conference proceedings and any publication that is not in English. As shown in Table 1 , after inclusion and exclusion criteria were applied to the 1,401 publications identified in the first level phase, 163 studies remained for inclusion and review.
Using a combination of Mendeley Desktop Version 1.14.1-dev7 for Mac, Atlas.ti 7.1.7 for Windows 7, and Microsoft Excel for Mac Version 15.17, these 163 publications were then read through completely. During this process, in addition to capturing a panel of bibliographic data and key sensemaking notes, each publication was distilled down to its respective "conversation" 30 , or core message and used as a basis for categorizing into like and meaningful similarities. Though the use of "conversation" as a tool for categorizing is limited due to issues of subjective interpretation, for the purpose of this review it proved to be sufficiently robust to be successful.
Following the completion of this first level review, a second level review was undertaken to mitigate any limitations that the subjectively chosen 18 EBSCO search strings might incur on the comprehensiveness of the first level search. This also mitigated any unforeseen limitations of the EBSCO database itself. This second level review was completed by performing a "downstream" literature review of the bibliographies of each of the 163 captured first level search publications using the same inclusion and exclusion criteria. This surprisingly resulted in the inclusion of an additional 141 publications which, after being reviewed, analyzed and categorized, were added to the first level results. After including these 141 to the 1 st level search of 163 and including one stochastically discovered iv Published academic focused books are often much more comprehensive than a single academic study thus complicating the ability to capture a single conversation. However, as many books are built on previously published research papers that were foreseen to be captured within the scope of this paper, it was anticipated that this exclusion decision to be of minimal consequence. This proved to be true.
publication from some informal exploratory reading, the combined number of publications included and categorized for this systematic literature review was 305.
ResUlTs aND CaTegORIzaTION
Among these 305 publications, 1986 is the first year that research is identified. These first four papers were focused on a combination of university-industry relations and technology transfer [31] [32] [33] [34] . These would have been highly relevant issues at that time due to the recent passing of the Bayh-Dole Act (1980), a key US legislation freeing the way for commercialization for federally funded basic research.
From this time forward, as Chart 1 shows, the activity in academic research of business model related dynamics in this industry increases with a clear explosion in publication activity starting from 1996. From this point, the leading research activity was focused on the dynamics of alliances, collaboration 4 "Biotech*" AND "Activity System*" 0 0 5 "Biotech*" AND "Business Process*" NOT "except biotechnology" 6 1 6 "Biotech*" AND "Platform*" NOT "except biotechnology" 160 3 7 "Biotech*" AND "Business framework*" NOT "except biotechnology" 0 0 8 "Biotech*" AND "Business structure*" NOT "except biotechnology" 1 0 9 "Biotech*" AND "Infrastructure*" NOT "except biotechnology" Of further interest is the year 2000 when the term "business model" started to appear explicitly in the titles. [35] [36] [37] In addition, of the 305 included publications, only 13 are directly focused on some type of specific business model related suggestion. Lastly, Tables 2 and 3 show respectively the ten journals with the most publications and the ten most prolific authors identified in this research. In effect, this is where the academic conversation is occurring about business model innovation in the biopharmaceutical industry.
ReseaRCh CaTegORIzaTION
After inductively categorizing the 305 publications based on the similarity of their conversations, 12 separate categories were determined and are shown below in Table  4 . Though some overlap does exist in their respective Chart 1: Research categorized by year of publication concepts and dynamics, they are sufficiently independent of each other to be informative. Following Table  4 , each of these 12 categories are addressed both with a summary narrative and a corresponding conversation table. The conversations in the tables have been distilled due to space limitations for inclusion into this paper.
The Landscape of BiopharmaceuTicaLs
The Landscape of Biopharmaceuticals comprises 48 publications related to the structure of the biopharmaceutical industry including its history and the dynamics that led to its development and periodic transitions. It also includes the economics of the industry both at a macro and micro level, the industry topology and interaction workflows among its stakeholders and how all of these dynamics vary by national organizational structure. As shown in Table 5 below, these publications have been split into 5 subcategories.
History and Development contains 12 publications that focus on the history and the evolution of the medical biopharmaceutical industry. It covers its institutions from its inception as a nascent chemistry based pharmaceutical industry in the 19 th century following multiple subsequent and overlapping technological paradigms 38 through key respective developmental and transitional dynamics into the modern biopharmaceutical industry. Common among this collection of research are publications focused on understanding what Coriat, et al. 39 describe as this industry's "Division of Scientific Labor", that is, basic research oriented academic and not-for-profit organizations vs. applied research focused for-profit organizations. The interaction of these two divisions of labor and the stakeholders, issues and policies affecting their interaction forms the narrative of the historical development of this industry and indeed is one the keys to understanding its current state and future trajectory. As an example, Hopkins et al. 40 point out that due to their closer relationship with university basic research, pure biotechnology companies have been causing a vertical disintegration of the pharmaceutical FIPCO models.
Topology and Operational Dynamics contains 14 publications that focus on the unique fragmented structure of this industry in terms of the many types of stakeholders and the dynamic information flows between them including the evolutionary adaptive responses leading to its current structure. 41, 42 For example, Niosi 43 through his use of Complex Adaptive Systems as a model of analysis, discusses the evolving nature of these dynamics by showing how the biotech industry is an evolving complex system of interdependent institutions. He goes on to highlight that solutions to increasing innovation within this industry are thus a function of lessening the natural resistance that stakeholders within this complex archipelago may exhibit.
National Institutional Structures contains 8 publications that focus primarily on the role that national institutional structures and cultures play on the fertility of their respective national biotechnology industries. These include research comparing relative advantages in a liberal market economy like the U.S.A. vs. a coordinated market economy such as Germany. 44 It also includes comparative differences in academic-industry relations among countries such as the perceptions governing academic careers and also industrial relationships and governmental policies influencing academic relationships with industry.
45,46
Market Success, Cost and Profitability contains 8 publications that focus on the cost of drug and therapy R&D. Although there is a consensus that this is certainly an expensive industry in which to do business and becoming increasing more so, there is some disagreement on profitability given current approval success rates. For example, though Glick 47 points to the success of current biotech business models, citing industry revenue and profitability figures, Grabowski et al. 48 point to the skewed distribution of profitability in this industry and highlights in his analysis the average mean which is barely above the cost of capital. Despite this, Lazonick & Tulum 49 show how, due to speculative investment, sociology, and government R&D support policies, significant investment will continue to flow into this industry regardless of its profitability.
Role of Government Policy contains 6 studies that focus on the role that government policy can play in improving the fertility of regional biotechnology environments. For these studies, there appears to be a general consensus that government policy plays a key role in the promotion of a healthy biopharmaceutical industry, particularly in promoting the commercial translation of research from academia into industry through policies and legislation. A good example of this is the 1980 implementation of the Bayh-Dole Act in the U.S.A. and the role that it played in motivating universities to commercialize their research.
driving facTors for Business modeL innovaTion
Driving Factors for Business Model Innovation comprises 21 publications related to the underlying issues 57 
11
Transformation of US pharma from manufacturing apothecaries to research institutions was accomplished through university engagement. Public-private collaborations in biotechnology play significant roles in building firm-based and policy-making capabilities.
Papaioannou, 2011 63 
7
The shift in tacit and exploration knowledge to DBFs signifies a crisis for multinational drug companies. that drive the opportunity for business model innovation. As shown in Table 6 these publications have been divided into 4 subcategories: Strategic Decision Factors contain 3 publications that are focused on how strategic decisions play a role in the opportunity for business model innovation. For example, where a firm chooses to place its R&D operations 85 or whether to conduct manufacturing in-house 86 are issues that can affect a firm's proximity to or receptivity toward breakthrough ideas in a novel business model. Relationship Orientation relates to 5 publications that form a consensus on the importance that sharing and integration across biopharmaceutical industry stakeholders play in the innovation of business models. 87, 88 Multiple authors agree that there exists a changing dynamic among university policies toward its relationship with industry 89, 90 which in turn identifies an area of opportunity for commercial translation models.
Exogenous Market Factors include 9 publications focused on the macroeconomic, legislative and technological changes with which firms must constantly adapt. In sum, these publications help to understand the various external challenges that could be influencing adaptive business model responses. As a strong example, Pisano discusses the various business models prevalent since the 1970's. 91 Important, to his discussion is that over these 40 years, different types of business models have been prevalent due to a unique set of economic, legislative and technological factors with which they, in each respective era, were best suited to address. As these factors changed, so did the business model. National Institutional Frameworks make up 4 publications that point to the impact that different features of national institutional frameworks play on the fertility of business model innovation. In essence, factors such as relative access to venture capital, organization of academic research training and careers, labor market regulation and governmental science policy all play a role, either restrictive or promotional, in business models innovation efforts.
92,93 drivers of Business modeL choice
Unlike the previous section which is framed on a macroeconomic perspective, this category consists of 29 publications that are focused on a company-specific perspective. That is, why biopharmaceutical firms, 3 Biotech business models must manage risk over long periods of time and foster integration across an array of disciplines and knowledges. themselves, choose the type of business model they do. As shown in Table 7 these publications can be further divided into 4 subcategories: Various Dynamics Affecting Business Model Choice include 11 publications focused on various factors that influence the choice of business model that a firm engages. Though many factors are studied, the major factors on which authors agree is the impact that funding availability has on the type of business model chosen. For example, Bigliardi, et al. 104 along with Fisken & Rutherford 105 show how low access to investment capital channels business model choice toward service or platform models and away from therapy development based models. The former typically requires less startup capital and reaches revenue generation sooner. Other issues on which authors find consensus are the concerns that a firm has of having its intellectual property appropriated by an alliance partner. 34, 106 Thus, choice of business model can be one way of mitigating this risk.
Considerations for Vertical Integration are a group of 6 publications focused on the comparative advantages of and considerations for relative levels of vertical firm integration. This collection of research encompasses the important risks and advantages of pursuing (or not pursuing) a fully vertically integrated business model. 107 For example, Papadopoulos 36 discusses how pursuing full vertical integration mitigates the risk of a platform model firm's technology becoming redundant and obsolete.
Impact of National Institutional Framework includes 8 research publications focused on revealing what impact national institutional frameworks play on business model choice and success. These authors show, for example, how dedicated biotechnology firms (DBFs) in Europe tend to pursue models focused on services and platform technologies due to the relative lack of government industry support, relatively low level of cooperation between academia and industry and weak equity finance infrastructure. 108, 109 Business Models Change Dynamics are 4 publications focused on the dynamics of why biopharmaceutical firms change their business model over time. These dynamics include new commercial opportunity recognition 110 , the opportunity to capture more value from their discovery efforts by expanding toward therapy development 111 or even a natural evolutionary trend toward therapy development after founding due to resource constraints.
112
Business modeL suggesTions
Business Model Suggestions are a grouping of 13 publications that address various models for innovation in business models. Throughout these publications, there 3 US type business models and structures must be adjusted for the national framework peculiarities of each respective country. is a consensus that due to the increasing scientific complexity of this industry, some form of sharing or decentralized distribution of responsibility is a key factor for increased productivity and lower costs. Among these is included suggestions for the use of virtual company business models utilizing high levels of outsourcing 129, 130 and the use of open innovation models. [131] [132] [133] . See Table  8 below.
compeTencies required for success
No matter the type of business model chosen, each business model requires different firm level competencies for success. As shown in Table 9 below, this category comprises 7 publications that focus on the critical nature that various firm-level competencies play in a firm's success and in its ability to utilize various business models. Specifically, this research includes the importance that experienced managers with business management competencies play in firm's success. Indeed, a firm's ability to acquire or develop these individuals is a key performance differentiator. 142 This is especially so since managers with this experience are in shortage. 143, 144 Other publications include research on the importance that a firm's ability to stay aware and adaptive to changing market conditions plays on success. 145, 146 
facTors impacTing organizaTionaL performance
Factors Impacting Organizational Performance contain 39 publications that are focused on the dynamics that impact how an organization performs in the market. As shown in Table 10 below, these publications are further divided into 6 subcategories: Strategy Specific Factors are seven publications that focus on the strategic decisions that biopharmaceutical firms can make that affect their success. The areas on which these authors focus are varied but as examples include where in a firm's value chain to place its innovation focus (e.g., R&D, manufacturing or marketing), external vs. internal orientation and timing of key activities. 149 It also includes the role that a risk management plan should play in a firm's strategy. 150 Organizational Competencies includes 9 publications that are focused on various aspects of a firm's ability to operate successfully in the biopharmaceutical environment. These include publications which support how a firm's competence through its employees to transfer, integrate and manage knowledge drives a firm's success. 151, 152 They also include research that explains the unique marketing requirements in this industry and the competencies required for success.
153-155
Strategic Alliance Usage and Management are a grouping of 7 publications that focus on the importance that alliances at multiple levels play on the success of a biopharmaceutical firm. These authors reach a consensus that the ability to create external linkages especially those with complimentary assets are critical to organizational performance.
156-158
Various Factors are 10 publications each of which is focused on separate drivers of firm performance. These include the importance of independent management skills 159 , the impact that good management of corporate reputation plays 160 , understanding the dynamics of market demand for biopharmaceutical products 161 and the use of rNPV analysis in product portfolio risk diversification. 162 Fertility Factors is a group of 5 research papers that are focused on the underlying dynamics that affect the fertility of the environment in which a firm is trying to succeed. Specifically, these factors include access to an outstanding research university, advocacy leadership, strong risk financing, an entrepreneurial culture, and appropriate real estate, all bound together through an intensive information exchange network. 163 It also includes research on the Porterian dynamics that can affect a firms ability engage this environment to build its firm specific value driving assets. 164 Survival Strategies includes a single publication by Patzelt & Audretsch 165 in which they address the options that firms have to survive when financing markets become hostile, and venture capital funding dries up. Complementing a development portfolio with risk-reduced projects is an attractive way to ensure sustained growth. 
TechnicaL innovaTion drivers
Technical Innovation Drivers includes 45 publications that focus on the dynamics, both internal and external to a firm, that drive its technical innovation productivity. As shown in Table 11 below, these can be divided into 10 subcategories: Historical Overview of Innovation Drivers includes 3 research papers on the dynamics and drivers of technical innovation in the biopharmaceutical industry. These publications help to understand how this industry has historically organized itself to promote innovation including the use of scale, followed by R&D partnerships and then to industrial biocluster management. 188 Of particular interest is a study by Achilladelis & Antonakis 38 , who have analyzed the history of the industry over five consecutive and overlapping technical phases since the industry's inception in the 19 th century and shown why these phases came about and what caused them to change.
Cooperation and Networking includes 17 publications that focus on the benefits that cooperation plays on a firm's innovation success. Indeed, as the biggest subtopic within this category, it highlights the importance that researchers perceive cooperation to be in helping a firm to be more innovative. Key areas of consensus among these 17 publications include the benefits on technical innovation that a close relationship with publicly funded basic research institutions has 189, 190 and the innovation benefits on various dynamics from collaborating with firms across the value chain. 191, 192 
Size and Scale of Research Efforts and Corresponding
Issues consist of 3 studies that show the benefit that firm size has on technical innovative output. For example, Henderson & Cockburn 193 make a case for larger research efforts being more productive due to their economies of scale and scope and the resulting increase in spillovers and absorptive capacity.
Human Capital consists of 3 publications that focus on the dynamics that a firm's scientific human resources play on a firm's innovation output. This includes the impact that different scientist types play on the innovation process including the important role of star scientists. 194, 195 Organizational Controls include 6 papers that span various methods of organizational control that firms can use to enhance innovative output. As two examples, it contains research on the use of stage gate controls to channel creativity and reduce risk in innovation management 196 and the management of communication across the firm to enhance innovation. 197 National Institutional Environment is a subtopic containing 2 publications that, like in previous categories, shows how technology innovation specifically is affected by key underlying national structures and culture. 198 Proximity is a grouping of 5 publications that help to understand the effect that geographical proximity to certain institutions and bioclusters has on a biopharmaceutical firm's innovation in both basic and applied research. 199, 200 Knowledge Base Coherence and Competence are a grouping of 3 papers which agree about the complementary importance that a firm's scientific and technological competence and experience play in its innovativeness. While collaborative arrangements with universities are common, those with such linkages are not always the firms experiencing success.
201-203
Models for Understanding and Managing Innovation Processes consists of 2 publications each providing a
Levitte & Bagchi-Sen, 2010 271 
10
In partner selection decision making, partners with the ability for value creation might use that ability to appropriate value.
Diestre & Rajagopalan, 2012 246 
11
Firms with an in-house innovation history on one or few products are most likely to be attractive alliance partners with large economy firms.
De Mattos et al., 2013 247 
12
Collaboration should always be observed as coexisting with dynamics of competition. Oliver, 2004 272 
13
The basic-applied dualism to represent research activity type and the public-private dualism to depict organizational nature are redundant. Absorptive capacity study 1 Biotechnology firms differ in their ability to benefit from collaborative relationships based on their internal technological knowledge.
Arora & Gambardella, 1994
278 2 This is a strong correlation between the diversity of firms' development efforts and the success probability of individual projects. 
aLLiances/cooperaTion/coLLaBoraTion
Alliances/Cooperation/Collaboration is a collection of 51 publications that focus on various benefits, challenges and dynamics relevant to this industry in the formation and managing of alliances and various forms of cooperation. As shown in Table 12 below, these can be divided into 4 subcategories: Spatial Proximity Factors are a grouping of 3 publications that focus on the dynamics that govern the functional and geographic proximity in biopharmaceutical firm relationships. In sum, these publications help to understand the relationship between the type of knowledge being shared and its associated need to be geographically close. That is, the sharing of tacit knowledge tends to require closeness whereas encoded knowledge is not as sensitive to this and can be effectively shared between alliances over much greater geographical areas.
232,233
Benefits of Relationships comprises 14 publications that address the benefits that firms derive from various manner of cooperative relationships. One key area of consensus among these authors is the multiple benefits that an academic relationship can bring to a commercial biopharmaceutical company including access to commercially viable innovations, talented human resources, and lower R&D costs. 234, 235 Another, similar to that above, is the general benefit firms derive from formal and informal cooperations with each other including the development of new tacit knowledge and complementary capabilities.
1,236
Governance and Relationship Management is made up of 14 publications that focus on the how firms that are in alliances manage key important aspects of their relationships with other firms. These include a focus on how to protect against opportunism, where Deeds & Hill 237 Dynamics of Relationship Formation is a grouping of 20 publications exploring various dynamics of alliance formation (previous categories focus on the benefits, not on the process/dynamics). These publications include various factors influencing alliance decisions including what key issues influence organizations to enter into alliances such as opportunities for learning and growth or attempts to maximize product development performance 242, 243 , key internal firm issues and capabilities that influence alliance choice such as governance capabilities or appropriation culture 244, 245 and issues affecting alliance partner selection such as a demonstrated history of value creation and in-house innovation. 246, 247 This subtopic also includes research on other issues including changing norms in commercial academic relationships 248, 249 and a typology of organization mode choice for alliances.
aBsorpTive CapaciTy
Absorptive Capacity consists of 6 publications that address the enabling effects that the breadth and depth of a firm's existing technical knowledge plays on its ability to utilize external knowledge. This includes for example research on how absorptive capacity enriches collaborative relationships 278, 279 and a publication on the factors that drive a firm's absorptive capacity such as broad knowledge base and centralized R&D organization.
dynamics of InvesTmenT InTeresT
Dynamics of investment Interest is a grouping of 13 publications that focus on various issues and factors that drive investment interest from stakeholders into biopharmaceutical firms. The largest grouping focuses on factors that drive investment interest from potential alliance partners. These factors may include having a product late in the development stage or approval process 284 or willingness to give the larger partner management control. 285 Other groupings include a focus on what factors drive venture capital investor interest such as close relationships and geographic closeness. 286 See Table 14 below.
cLusTers
Clusters is a group of 17 publications that focus on the prerequisites and factors important to geographic cluster formation and the benefits associated with participating within them. These include the co-existence of both world-class scientific resources with the complementary business resources to translate this knowledge into a commercial product. 297 This pooling of resources focused on similar technology development provides firms the advantage of a common labor pool and access to key markets and customers 298 and importantly access to key basic research. 299, 300 Moreover, as is present in other categories, this category also includes research on how national institutional frameworks affect clustering 301 and includes research that shows how information flows and relationships within a cluster are a holistic group of interacting and overlapping dynamics. 302, 303 See Table 15 below.
neTworking
Networking is collection of 16 publications that focus on key dynamics of network formation and factors impacting a firm's utilization of these networks. See Table 16 below. In general, this collection of research makes clear that many factors exist that affect network formation in the biopharmaceutical industry and that network participation drives firm success. Key among these include the role that academic inventor-scientists play, through not only their own direct human capital contribution to a firm, but also through the contribution of their important social capital by which firms gain credibility and access to the greater network. 314 Indeed, the strength of this social capital can be considered an important strategic resource. 315 This collection of research also makes clear that as a firm's network develops, a specialized sub network develops which increase the options and opportunities to firms. 316 Particularly interesting is Owen-Smith & Powell's 317 use of a channel and conduit metaphor to describe the different types of knowledge spillovers that occur through network participation.
DIsCUssION
Through a systematic literature review, this research has identified, reviewed and categorized 305 academic research publications between the years 1976 and 2013 that are highly relevant to understanding the dynamics for business model innovation in the biopharmaceutical industry. Through the 12 separate areas of research identified, key issues for understanding business model innovation have been highlighted, and five specific areas of opportunity have been proposed. This research has revealed that a necessary prerequisite to understanding the opportunities for business model innovation in this very complex industry is to first understand the reason for the prevalence of this industry's historic business models and key national level differences that are affecting its innovation and commercialization success.
From its beginnings in the 19th century, the modern biopharmaceutical industry started as an industry using stochastic trial and error oriented research methods based primarily on chemistry and later organic chemistry. During this time a fully integrated business model It takes a whole community to build a biotechnology cluster but once built; the cluster can achieve a sustaining life that strengthens itself.
Nelsen, 2005 308 10 Sustainable clusters are linked to the existence of dense social networks across key personnel supporting career mobility.
Casper, 2007 309 
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Cluster advantages arise only after some years of existence in a cluster, and the companies have learned ways to "grasp" cluster advantages. (FIPCO) prevailed. Among the key reasons for this were the knowledge accumulation advantages that large economies of scale and scope gave an organization when all of its knowledge was contained and containable "in-house." Indeed, as evidenced through the successive and overlapping Kondratiev type long waves of technological focus, that Achilladelis & Antonakis 38 extensively describe, the FIPCO model was well suited in its ability to allow the pharmaceutical industry to take advantage of its evolutionary accumulated expertise in organic chemistry and channel it toward the discovery of new products and product classes.
Then, starting in the late 1970's everything changed with the appearance of the first biotechnology-based medical therapies. Their presence and utilization represented a conundrum for organic chemistry based pharmaceutical companies. On the one hand, this new technology offered them an opportunity to bring new innovative therapies to market by offering a complementary alternative to their prevailing random discovery The "open architecture" of biotech firms facilitates product development. However, the lack of a well-developed governance structure poses risks.
Powell, 1999 323 
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Participation in networks is found to vary according to the firm's size, stage of development and its sector of activity. based methods and potentially a way to reduce the time and cost to bring a therapy to market approval. However, it also exposed a disruptively innovative threat since biotechnology companies using these new therapies could themselves develop as an independent and competitive industry. Indeed, this threat was quite real since the prevailing FIPCO models that had been so successful for them for over 100 years would not necessarily prevail in this new fragmented technological environment. FIPCO models were built on the advantages of having a very deep knowledge in predominantly one key technological area, organic chemistry. This R&D was conducted mostly within the walls of their own organizational R&D units with only relatively limited need to be actively engaged with external research centers around the world. However, a shift to an externally focused R&D paradigm was exactly what this new decentralized biotechnology focused world was requiring. Biotechnologies, (initially molecular biology and genomics) were a new complex knowledge base and required such adaptive responses that firms could capture only fragments of the new technologies. 41 In addition, it was dispersed in universities and basic research centers around the world. As a result, small specialized product and service firms were best suited to develop and commercialize these new various biotechnologies, leading to what Pisano 3 would call an archipelago of specialization.
Complicating matters was that all countries were not equally ready to take advantage of these new technologies. Because these new biotechnologies follow a co-evolutionary progression of scientific, technical, industrial, clinical and regulatory changes, the institutions governing these respective changes must coordinate their efforts. 40 However, national institutional structures and national institutional culture play an important role in how scientific institutions and commercial entities coordinate and respond to new technologies. As countries typically differ on welfare systems, employment law and conventions, training systems, financial markets, and legal systems 92 , the comparative mix of these factors affect the relative rates of innovation and the fertility of different types of business models.
One key aspect of this is the important role that academics perceive themselves to have in commercializing their technologies and, in turn, how active universities are in seeking commercial opportunities for the science that derives from their personnel. In general, U.S. universities have a strong culture of collaboration with industry, European universities less so. 43 Moreover, the direct involvement of European academic researchers in commercial endeavors is relatively limited versus that of the US researchers. 54 This is an important key in the understanding the opportunities for business model innovation in this industry due to the cultural and structural roadblocks that exist. If an academic scientist has little desire to pursue anything other than his or her own career enhancing publications or the university fails to provide a healthy level of support in pursuing IP protection for its researchers' discoveries, many important ideas and innovations may never see the commercial "light of day. Indeed, this relationship to academia is a particularly important topic of interest due to the changing Mertonian norms and dualisms of relationships caused by traditionally "independent" academia becoming more intertwined with biopharmaceutical commercialization. 248 Intertwined within these academic perceptions are the national level legislations that influence the private commercialization of publically funded research. In the U.S.A., among many key legislations that have been historically instrumental in the lead-up to its present ability to be a world leader in biopharmaceutical innovation and commercialization are the 1862 and 1890 Morrill Act leading to applied science focused land grant universities 99, 329 , 1980 Baye-Dole Act which opened the way for federally funded research to be owned and commercialized by the inventor 50 , the Diamond vs. Chakrabaty ruling by the US Supreme Court that genetically engineered life forms were patentable 87 , and the 1984 NASDAQ listing requirement reforms.
39 Though the U.S.A. has been the leader in enacting these liberalizing governmental actions, other nations are only slowly following suite. These include, for example, Germany's 2002 adjustments to its Arbeitnehmererfindungsgesetz (ArbnErfG), its employee discovery law which attempted to create BayeDole Act similarities. v Another key national structure issue affecting the fertility of business model innovation is the relative strength of a nation's private equity investment market. With a relatively weak equity capital investment market, such as those of continental Europe where bank driven forces prevail, new start biopharmaceutical companies are challenged to find the large amount of investment capital needed. This leads to a prevalence of choosing business models that are service or platform based since they require less capital versus a therapeutic development focused model. Lastly, is the role played by differences in national labor markets. From an industrial perspective, small and medium-sized enterprises need flexibility in their labor resources since a company may need to react quickly to an opportunity or threat. Therefore, the relatively protected and less flexible labor markets of the v Unlike the Baye-Dole Act which moved the ownership of an invention closer to the inventor themselves, the 2002 ArbnErfG changes moved the ownership to the employer with the promise of employee compensation upon successful IP licensing/sale.
world outside of the US can be a challenge to a firm that needs to quickly downsize.
five areas of OpporTuniTy for Business ModeL InnovaTion
External orientation
By far the most common theme identified in this research is how important an external orientation is as a source of advantage in the modern biopharmaceutical industry. Specifically, this includes openness to sharing and mining for ideas outside of the firm through a focus on collaboration and learning. This is in stark contrast to the historical role that a full vertically integrated business model played as an advantage for success in this industry with its relatively stronger internal focus. Indeed, this body of research is highly focused on gaining the advantages of full vertical integration but as a decentralized entity through optimizing the advantages and efficiency of diverse relationships to attain the same end and at a lower cost. As mentioned earlier, 5 show in their research that when the knowledge base of an industry is both complex and expanding, and the sources of expertise are widely dispersed, certainly the case for today's biopharmaceutical industry, the locus of innovation will be found in networks of learning, rather than in individual firms. Thus, the cumulative data from this review appears to show that a firm's ability to thrive in this network will be influenced by its ability to operate with a business model that competitively excels in its effectiveness to operate with an external focus.
Learning capabilities
Now, key to this ability to operate externally is a capability to recognize and absorb new opportunities when they appear and to learn cumulatively over time. 110 This is driven in part by the scope and coherence of a firm's knowledge base 201 which follows an evolutionary path dependency of successive experiences and endeavors. 202 This absorptive capacity is critical to innovation success. It is a key factor that allows a firm to recognize, assimilate and to exploit different types of knowledge 282 and is often the differentiator for success among firms. Thus, it is not only important to develop broad and deep networks with external experts but more so, it is important to improve absorptive capacity to utilize this expertise. Thus a business model must include a strong network development and maintenance capability. This should include relationships with stakeholders at all levels of the industrial value chain especially with those in academia as it provides a strong source to commercially viable innovations, knowledge spillovers and talented people. 234 Of particular importance in this ability are policies focused on developing a well networked technical team on both formal and informal levels 177 and a team that is committed to broadening their learning so as to enhance their absorptive capacity to capture knowledge spillovers. 193 Included in these policies, for example, should be assurances that this team consists of the right composition of scientist types, what Stokes 330 and Subramanian 195 call "Pasteur" scientists and "Edison" scientists. "Pasteur" scientists are applied scientists who also have a strong basic research focus. Their higher publication rates give a firm better informal access to university-based academic scientists. "Edison" scientists, on the other hand, are pure applied researchers. They excel at patenting and translating basic research. This recognizes that a firm's scientists are not homogenous and that they play different roles in the knowledge production process and interact differently with the knowledge absorption process. Indeed, the findings of this research have been consistent with how this importance can not be understated since it is a critical dynamic to the virtues of solid network development. The value of a key scientist is not just that of his scientific capital contribution but also that of his social capital. This helps not only with obtaining greater embeddedness within relevant networks and the scientific community 314 but also with conveying a signal of confidence to other relevant stakeholders such as investors and alliance partners.
Cluster participation
Complementary to the development of these learning capabilities is firm location, particularly a location that is close to a strong and technologically relevant biocluster. Such, a cluster is one that is anchored by a strong science base typically represented by a top science university or universities 304 whose gravity attracts the complementary orbit of multiple other stakeholders necessary for commercial success. These stakeholders include finance resources, a local supportive government providing fertility enhancing resources 297 , access to markets and customers 298 and generally a dense social network of key personnel that, among other advantages, supports access to a stable common labor pool through its provision of career mobility and sustainability. 309 Thus, the importance of cluster participation will remain particularly critical as the trajectory of business models continues to follow a decentralization pattern of specialized players relying on alliances and outsourcing.
Qualified business management team
Though much of the research revealed in this review is focused on the importance that an external orientation and acumen plays on firm success, including the importance of key characteristics of the technical and scientific team, a clear separate body of work is focused on the importance that a qualified independent management team plays on the ability to commercialize innovations. In this industry, this is indeed of critical importance since, even with an innovative new technology, a company may still fail commercially without the right management expertise on board. However, it can be a significant challenge for a cash-strapped new start biopharmaceutical company to obtain and retain top commercial expertise due to the lack of financial resources and also to the perceived career threat to that person of onboarding such a high-risk endeavor. However, though the research from this review shows that these challenges can be mitigated through the use of strategic alliances and a strategy focused on strong network development 156 , the shortage of qualified, experienced business managers remains a problem.
Organizational controls
Lastly, this research reveals that effective organizational controls are critical for any business model to be effective in this highly complex and high-risk industry. These controls will be an important tool to address both internal and external dynamics of survival and success. Internally, they are important to enhance communication and knowledge proximity across the firm. 225 For example, the use of stage gates can be used to channel creativity and reduce risk 196 including prudent resource allocation. Externally, in the increasingly fragmented nature of this industry, many challenges have to be overcome if indeed a firm is to operate at similar economies of scale and scope as would a fully integrated company. They include the tendencies toward opportunistic behavior that exists in alliances and relationships.
2, 237 Thus, in addition to formal mechanisms to dissuade this behavior such as the use of contracts or ownership equity positions, 238 companies will need to develop other creative mechanisms to complement these tools.
CONClUsIONs
This paper systematically captures and inductively explores a defined set of academic literature for insights into how the biopharmaceutical industry, through the use of business model innovation, could continue to drive its technical innovation toward new and innovative therapies while at the same time reduce the significant costs and time to market. What is found is that although no "magic bullet" of a single clever new business model has been revealed, five areas of opportunity have been identified that could be the source of incremental innovation in this area. Continued focus in these five upstream value chain areas have the ability to unleash greater potential value from networked collaboration among the widely scattered sources of expertise in this industry including the ability for a firm to recognize, functionally absorb and utilize the fruits of these collaborations and govern the required process successfully. However, as this research reveals, any innovation must incorporate national institutional structure limitations on these innovations, such as the creation of appropriate incentives for academic researchers to push out their IP while simultaneously addressing their career linked publication needs.
FURTheR ReseaRCh
Like explicit research on business models as a standalone concept, business model research in the biotechnology industry is still relatively young. Indeed, this research reveals that only since the year 2000 have business models been an explicit focus in biopharmaceutical research. Moreover, of the 68 publications identified in this systematic review that specifically use the word "Business Model," there remains no clear consensus of what exactly is meant by this term, some implicitly mean revenue model, others mean strategy while others are referring to organizational structure. Therefore, this field could benefit by research focused on the comprehensive defining nature of the biopharmaceutical business model itself versus a specific component or dynamic of it. Also useful would be empirical comparative research on performance dynamics between business models, especially relating to external cooperation mechanisms with longitudinal or geographical components. 
